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Effect of Age on the Profile of Psychotropic Users: Results from
the 2010 National Ambulatory Medical Care Survey
Donovan T. Maust, MD,*† David W. Oslin, MD,‡§ and Steven C. Marcus, PhDk¶
OBJECTIVES: To describe the effect of age on psychotro-
pic coprescribing, psychiatric diagnoses, and other clinical
characteristics.
DESIGN: Analysis of the National Ambulatory Medical
Care Survey.
SETTING: A national sample of outpatient visits to physi-
cians (N = 2,406) in office-based practice in 2010.
PARTICIPANTS: Adults prescribed psychotropic medica-
tion (N = 31,229).
MEASUREMENTS: Office visits at which antidepressant,
anxiolytic, sedative, hypnotic, antipsychotic, or mood
stabilizer medications were prescribed were grouped
according to participant age (21–64, ≥65) and then com-
pared within each medication class on visit characteristics.
and then compared according to variables including pro-
vider type, sex, and race; presence of diagnosed mental ill-
ness; prescription of other psychotropic agents; total
number of chronic conditions; time spent with physician;
and total number of medications.
RESULTS: In 2010, there were 90.3 million antidepres-
sant office visits; 77.7 million anxiolytic/sedative/hypnotic
visits; 15.5 million antipsychotic visits; and 9.5 million
mood stabilizer visits. Nonpsychiatrists prescribed the
majority of psychotropic medications for every class and
age group; 17.3% of older adult antipsychotic visits and
44.9% of younger adult antipsychotic visits were to a psy-
chiatrist (chi-square = 19.58, P = .001). Older adults in
every medication class were less likely to have a diagnosed
mental disorder.
CONCLUSION: Older adults prescribed psychotropic
medication were less likely to have a diagnosed mental
disorder than their younger counterparts. Efforts to pro-
mote quality prescribing should seek to minimize nonspe-
cific use of psychotropic medication. J Am Geriatr Soc
62:358–364, 2014.
Key words: pharmacoepidemiology; psychotropic pre-
scribing; National Ambulatory Medical Care Survey
The use of prescription psychotropic medication inolder adults is an area of important clinical signifi-
cance. Older adults are more likely than younger adults
to experience adverse polypharmacy-related events1,2
given concomitant pharmacodynamic and pharmacoki-
netic changes.3 Even selective serotonin reuptake inhibi-
tors, long thought to be relatively benign, have been
associated with risk of falls and fractures in older
adults.4,5 The latest version of the American Geriatrics
Society Beers Criteria includes virtually every class of
psychotropic medication as potentially inappropriate.6
Psychotropic medication use in older adults has come
under increased scrutiny, but recent pharmacoepidemiolo-
gy has largely focused on specific diagnostic groups or
institutional settings, such as the dementia-related use of
antipsychotics7,8 or psychotropic use in long-term care
settings,9,10 whereas broad studies of nationwide psycho-
tropic use have focused on office-based psychiatry.11–13
These investigations, although critical, do not consider
psychotropic prescribing to community-dwelling older
adults, who are more likely to be seen and receive pre-
scriptions in nonspecialty settings serving a wide range of
patient ages than in specialty settings.14
Strategies to improve mental health services have, in
part, focused on improving the underdetection and under-
treatment of mental illness. At the same time, and perhaps
as a side effect of these efforts’ success, use of psychotro-
pic medication in the absence of a documented psychiatric
disorder is garnering attention. This phenomenon has
been demonstrated in a number of large, survey-based
analyses of antidepressant15,16 and antipsychotic13,17,18
use. Complementing these large survey analyses, results
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from a state-wide mental healthcare management program
demonstrated that nearly 48% of older adults prescribed
a new psychotropic medication did not meet criteria for
any Axis I psychiatric disorder.19
Given the limited supply of clinicians who see an
exclusively geriatric population, most providers treat peo-
ple across the adult age range. It is therefore important to
understand the association of age with the demographic
and clinical characteristics of those prescribed psychotropic
medication, such as coprescribing and presence of psychi-
atric diagnoses. Prescribing should be based on the
presence or absence of diagnostic criteria, so the character-
istics of those prescribed psychotropic medication would
not be expected to vary according to age. Finding other-
wise would suggest that patient age influences provider
prescribing, perhaps in an adverse manner. Examining
medication use is particularly important for older adults,
who are more sensitive to the side effects of medication
and at greater risk of polypharmacy-related adverse effects.
The decision to prescribe should be patient-centered, such
that a given set of symptoms triggers prescribing, regard-
less of age, when controlling for other diagnostic and clini-
cal characteristics. Based on previous work, it was
hypothesized that older adults prescribed psychotropic
medication would be less likely to have a diagnosed men-
tal illness than their younger counterparts.
METHODS
Source of the Data
Data for these analyses were obtained from the National
Ambulatory Medical Care Survey (NAMCS), a national
survey administered by the National Center for Health
Statistics (NCHS) of the Centers for Disease Control and
Prevention designed to “provide objective, reliable infor-
mation about the provision and use of ambulatory medical
care services in the United States.”20 This study used data
from the 2010 survey year, the most recent available.
Survey Design
The National Ambulatory Medical Care Survey is a
national probability sample survey of office-based and
community health center–based physicians that yielded
31,229 patient encounters in 2010. Physicians in the spe-
cialties of anesthesiology, pathology, and radiology are
excluded, as are encounters such as house calls and those
in institutional settings (e.g., nursing homes). The 2010
NAMCS sample included 2,406 eligible physicians, with
a response rate of 58.3% overall and 53.5% of psychia-
trists. Each physician is assigned to a 1-week reporting
period, with the physician or office staff recording data
from a random sample of visits. Data are obtained on
patient symptoms, sociodemographic characteristics, and
medications ordered or provided. The survey instrument
captures the top three visit-related diagnoses and every
NAMCS visit is also assessed for the presence of 14 spe-
cific chronic conditions (e.g., arthritis, chronic renal fail-
ure, ischemic heart disease).
Adjusting for survey design elements allows analyses to
represent total annual visits to U.S. office-based physicians.
Psychotropic Drug Visits
The National Ambulatory Medical Care Survey uses the
Lexicon Plus proprietary database (Cerner Multum, Inc.,
Denver, CO) for medication classification. A psychotropic
visit was defined as a visit in which one medication from
one of the four psychotropic classes was prescribed,
ordered, supplied, administered, or continued, with psy-
chotropic medications categorized according to the Mul-
tum classifications (Table 1): antidepressants, anxiolytic/
sedative/hypnotics (hereafter referred to as “anxiolytics”
for simplicity), and antipsychotics. A fourth category for
mood stabilizers was created to capture office visits that
included carbamazepine, lithium, lamotrigine, valproate,
or divalproex. Antipsychotic visits were further subclassi-
fied into encounters that used second-generation antipsy-
chotics (Table 1). If an encounter involved psychotropic
medications from multiple classes, the visit was included
in each appropriate medication group.
Diagnostic Groups
As part of the information collected at each NAMCS
encounter, up to three diagnoses were included using the
International Classification of Disease, Ninth Revision,
Clinical Modification (ICD-9-CM) and the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition
Table 1. Psychotropic Drugs Reported in the 2010
National Ambulatory Medical Care Survey
Antidepressants Anxiolytics Antipsychotics
Mood
Stabilizers
Amitriptyline Alprazolam Chlorpromazine Carbamazepine
Amoxapine Buspirone Fluphenazine Lamotrigine
Bupropion Butabarbital Haloperidol Lithium
Citalopram Butalbital Loxapine Valproate or
divalproex
Clomipramine Chloral hydrate Molindone
Doxepin Chlordiazepoxide Perphenazine
Duloxetine Clonazepam Pimozide
Escitalopram Clorazepate Prochlorperazine
Fluoxetine Diazepam Thioridazine
Fluvoxamine Diphenhydramine Thiothixene
Imipramine Doxepin Trifluoperazine
Maprotiline Doxylamine Second Generation
Mirtazapine Estazolam Aripiprazole
Nefazodone Eszopiclone Clozapine
Nortriptyline Flurazepam Olanzapine
Paroxetine Hydroxyzine Paliperidone
Phenelzine Lorazepam Quetiapine
Protriptyline Meprobamate Risperidone
Selegiline Midazolam Ziprasidone
Sertraline Oxazepam
Tranylcypromine Pentobarbital
Trazodone Phenobarbital
Venlafaxine Prazepam
Pyrilamine
Ramelteon
Temazepam
Triazolam
Tybamate
Zaleplon
Zolpidem
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(DSM-IV). Encounters were then classified as to the pres-
ence or absence of a given condition using broad
diagnostic categories.18,21 Those with an ICD-9-CM visit
diagnosis code of 296.2, 296.3, 298.0, 300.4, 309.1, or
311 were defined as encounters for a depressive disorder.
Similar criteria were applied to define treatment for psy-
chotic disorders (295.00–295.99, 297.00–298.09 (except
298.0), 298.30–298.99), bipolar disorder (296.0. 296.4–
296.8, 301.13), and anxiety disorders (293.84, 300.00–
300.09, 300.20–300.29, 300.3, 300.7, 308.0–308.9,
309.21, 309.81, 312.39, 313.0, 313.21, 313.23). Groups
were also created for encounters that included a diagnosis
of a seizure disorder (345), insomnia (307.40–307.49,
780.50–780.59), and dementia (291.2, 294.10, 294.11,
331.0, 331.1, 331.82). Last, a category was created for
encounters with no psychiatric diagnosis (290–319).
Other Characteristics
Encounters were classified into two groups according to
participant age: younger (21–64) and older (≥65) adult.
Visits were subsequently classified into mutually exclusive
groups according to provider type (psychiatrist, other),
sex, and race (white, other). The total number of chronic
conditions, time spent with the physician, and total num-
ber of medications were also included.
Statistical Methods
For each of the four medication classes, the number of
younger and older adult office-based psychotropic visits in
2010 was determined and stratified according to provider
type and patient sex, race, diagnostic groups, and use of
medication from the other psychotropic classes. Within
each medication class, the age groups were compared on
each categorical variable using the chi-square test. Total
number of chronic conditions, time with the physician,
and number of medications were also compared between
age groups using the Student t-test. Then, within each
medication class and using age group as the independent
variable (0 = younger adult, 1 = older adult), a simple
logistic regression model was created for each categorical
demographic and clinical variable (dependent), generating
an odds ratio for psychotropic prescribing for older adults
relative to younger adults for each dependent variable.
Likewise, a simple linear regression was used for the con-
tinuous dependent variables (number of chronic condi-
tions, time spent with physician, total number of
medications). Subsequent regression models were then con-
structed with age group as the independent variable and
each demographic and clinical variable as the dependent
variable in turn, controlling for the remaining variables.
Analyses were adjusted for visit weight, clustering,
and stratification using survey design elements provided by
NCHS. All were conducted using SAS Enterprise Guide
4.3 (SAS Institute, Inc., Cary, NC) using two-sided analy-
ses with a = .05.
RESULTS
In 2010, there were 90.3 million antidepressant office visits,
77.7 million anxiolytic visits, 15.5 million antipsychotic
visits, and 9.5 million mood stabilizer visits. Within each
medication class, the younger and older adult populations
varied in a statistically significant manner for the majority
of the demographic and clinical variables examined
(Table 2). Nonpsychiatric providers provided the majority
of prescriptions for all medications in both age groups. Only
a small portion of older adult psychotropic visits were with
psychiatrists, ranging from 3.5% of anxiolytic visits to
17.3% of antipsychotic visits. Older adults with psychotro-
pic visits were less likely to have a psychiatric diagnosis for
every medication class and every diagnostic group, and
65.2% of older adult antipsychotic visits noted no DSM-IV
diagnosis. Analyses of individuals with insomnia or demen-
tia yielded too few cases to meet NCHS standards for
reliable national estimation.
In the unadjusted regression models (Table 3), older
adult psychotropic users differed from their younger coun-
terparts in the majority of demographic and clinical char-
acteristics for all medication classes. For example, older
adults prescribed an antidepressant were 0.26 (95% confi-
dence interval (CI) = 0.19–0.35) times as likely as younger
adults to see a psychiatrist and 3.10 (95% CI = 2.39–
4.02) times as likely to have no DSM-IV diagnosis. In
addition, in the unadjusted linear regression, older adults
had 0.79 more chronic conditions, had visits that were
1.07 minutes shorter, and were taking 1.73 more medica-
tions than their younger adult counterparts taking antide-
pressants. Overall, older adults with psychotropic visits
were nearly three to five times as likely as younger adults
not to have a DSM-IV diagnosis.
Results of the multivariate regression models accord-
ing to medication class are also presented in Table 3. For
example, older adults taking an antidepressant were less
likely than their younger adult counterparts to be female,
more likely to be white, and less likely to have a diag-
nosed anxiety or seizure disorder or to receive concomi-
tant anxiolytics or antipsychotics. Older adults prescribed
antidepressants also had more chronic conditions, spent
more time with the physician, and were on more medica-
tions than their younger counterparts. For all four medi-
cation classes, older adults had more chronic conditions,
were taking more medications, and spent more time with
the physician than their younger counterparts, with the
exception of antipsychotics and mood stabilizers, with
older adults having shorter visits than their younger
counterparts.
DISCUSSION
To the knowledge of the authors, these are the first analy-
ses of national community-based psychotropic prescribing
to expressly describe how sociodemographic and clinical
characteristics vary according to age group.
In every medication class, older adults were less likely
to be diagnosed with a mental illness, with the majority of
older adults taking an antipsychotic not having a DSM-IV
diagnosis. These findings are generally consistent with pre-
vious analyses in the general adult population, such as the
finding that 26.8% of antidepressant users in 2005 were
diagnosed with depression21 or a 2005 to 2009 NAMCS
analysis showing that 15.8% of adults prescribed an anti-
psychotic were diagnosed with schizophrenia,18 but the
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current analyses are the first to show that psychotropic use
in the absence of a psychiatric diagnosis is higher in every
medication class for adults aged 65 and older.
Given that the NAMCS survey limits the number of
diagnoses listed to three, it may be that the mental disor-
der diagnoses of older adults with multiple medical condi-
tions were not included in the survey visit form. However,
the NAMCS survey assesses the presence of 14 specific
chronic conditions, and the average number of conditions
reported was low for both age groups, the highest being
just 2.3  0.03 in the older adult group taking antidepres-
sants. So although limited survey space may be a contrib-
uting factor, it is also possible that psychotropic
medications were being used in older adults in the absence
of a diagnosed mental disorder more commonly than in
younger adults. Providers may be providing psychotropic
medication for off-label uses; unfortunately, these survey
data do not provide any information on prescriber ratio-
nale. In addition, the list of chronic conditions assessed
was too brief to be informative in this respect. Although
off-label psychotropic prescribing is important to under-
stand in the older adult population, the nature of the
NAMCS data is not ideally suited to do so.
As expected, the majority of psychotropic prescribing
occurred in visits to nonpsychiatrists, a finding even more
pronounced for older adults, although in the multivariate
regression models for each class, this finding did not
remain statistically significant.
In the unadjusted analyses, visit duration was signifi-
cantly (if slightly) shorter for older adults in all medication
classes, but in multivariate analyses, for the antidepressant
and anxiolytic groups, this became a positive association.
Stepwise regression models (data not shown) demonstrate
that physician specialty primarily accounts for this differ-
ence, because older adults in these two classes overwhelm-
ingly see nonpsychiatrists with shorter visit times. In
contrast, older adult visits at which antipsychotics or
mood stabilizers were prescribed remain shorter than for
younger counterparts even in multivariate analyses. This is
unexpected and is a potential cause for concern, because it
is likely that older adults taking these classes of medica-
tions have significant comorbid medical problems and are
at risk for particularly poor care.22
The only class in which sex varied between the age
groups was with antidepressants, with older adult visits
slightly less likely to be female than the younger cohort;
this was even more pronounced in the multivariate analy-
ses. This finding may be related to the fact that the preva-
lence of depression is higher in women, although this
imbalance becomes less pronounced in older adults.23,24
Older adult visits for antidepressant and anxiolytics were
nearly three times as likely to involve older white individu-
als as were visits for younger adults; this finding did not
extend to the antipsychotic or mood stabilizer groups. This
racial difference is consistent with the finding that non-
white minorities are less likely to receive appropriate medi-
cation management.25,26
It is perhaps encouraging to note that the older adult
group was no more likely to be exposed to psychotropic
coprescribing than younger adults, and in many combina-
tions, this was less likely to occur for the older adult
group. Older adults were less likely to receive an atypical
antipsychotic than younger adults. Given that the evidence
of mortality risk in individuals with dementia has consis-
tently been shown to be higher with conventional antipsy-
chotics,27,28 it might have been expected that clinicians
would preferentially use atypical agents for older adults
than in the younger population.
An important limitation of this work is that clinical
assessments were not available for each of these encoun-
ters. It is likely, for instance, that a significant amount of
psychotropic prescribing is related to insomnia. This was
included in the analytical plan as a diagnostic group, but
there were too few cases to estimate annual visits reli-
ably. Likewise, psychotropic prescribing in older adults
may frequently be related to dementia, but as with
insomnia, there were too few cases recorded in each of
the four psychotropic groups to include dementia in these
analyses.
The need to identify and treat mental illness in
older adults must be balanced against the increasing
evidence of psychotropic-related adverse events.4,5 The
current work confirms previous findings that psychotro-
pic visits for older adults are less likely to be to a psy-
chiatrist.14 In addition, although previous analyses of
survey and administrative data have found that prescrib-
ing occurs in the absence of a diagnosed mental disor-
der,13,15–18 this is the first to document that this is even
more likely in older adults for every class of psychotro-
pic medication.
These findings follow the recent Institute of Medicine
(IOM) report on The Mental Health and Substance Use
Workforce for Older Adults.29 Although better access to
mental health specialists would ideally improve the speci-
ficity of psychotropic prescribing, this report notes that
“there will never be sufficient numbers” of specialists to
provide direct specialty care. Among other things, the
IOM report suggests training midlevel providers in pri-
mary care settings in geriatric mental health to help
screen and perform brief interventions. The evolution of
Medicare Accountable Care Organizations may provide
financial models that can allow health systems to invest
resources in these midlevel providers to perform care
management services that could promote screening and
monitoring of at-risk older adults.30 It is critical to
develop and fund strategies for general settings that
enable physicians to offer screening, education, and psy-
chosocial supports, providing options for care beyond
prescribing alone.
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